ArticleCurrent epidemiology reports2019
The changing epidemiology of primary liver cancer.
Article in Current epidemiology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 4 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis.Clinical and molecular hepatology · 2024Pooled it
- Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2023Pooled it
- Regular Aspirin Use Is Associated with a Reduced Risk of Hepatocellular Carcinoma (HCC) in Chronic Liver Disease: a Systematic Review and Meta-analysis.Journal of gastrointestinal cancer · 2023Pooled it
- Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Safety and efficacy of precision hepatectomy in the treatment of primary liver cancer.BMC surgery · 2023Trial
- Systemically delivered mRNA-LNPs transfect primary and secondary liver tumors.Molecular therapy. Nucleic acids · 2026Article
- CD177Gut · 2026Article
- Clinical and Genetic Determinants of Hepatocellular Carcinoma in a Turkish Cohort: Impact ofInternational journal of molecular sciences · 2026Article
- Exposure to Poly- and Perfluoroalkyl Substances and Risk of Hepatocellular Carcinoma in Male Patients with Cirrhosis Related to Hepatitis C Virus Infection.Liver cancer · 2026Article
- Article
- Machine learning-based identification of key genes underlying sex differences in hepatocellular carcinoma and targeted drug screening.Biomedical reports · 2026Article
- A rare but fatal outcome is hepatocellular carcinoma (HCC) progressing to the right atrial tumor thrombus and inferior vena cava.Radiology case reports · 2026Article
- Sonazoid-contrast-enhanced ultrasound for the histological diagnosis of hepatocellular carcinoma.World journal of gastrointestinal oncology · 2026Article
- Research Progress on the Molecular Mechanism of Metformin Regulating AMPK Signaling Pathway in Inhibiting Liver Cancer.OncoTargets and therapy · 2026Review
- Global, regional, and national burden and trends of liver cancer due to hepatitis B in young adults from 1990 to 2021 and forecast to 2030: insights from the Global Burden of Disease Study 2021.Internal and emergency medicine · 2026Article
- Echinacoside as a Novel Ferroptosis Inducer in Hepatocellular Carcinoma: Mechanistic Insights from TP53/SLC7A11/GPX4 Pathway Modulation.International journal of molecular sciences · 2025Article
- Hepatitis B virus core protein promotes liver cancer progression by stabilizing CANX and suppressing IRF7 transcription.Acta pharmacologica Sinica · 2025Article
- MicroRNA‑885‑5p regulates cell cycle progression in liver cancer cells.International journal of molecular medicine · 2025Article
- ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma.Scientific reports · 2025Article
- Cancer Incidence and Trends in Persistent Poverty Areas of California by Race/Ethnicity and Sex.Cancer medicine · 2025Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewIn prior decades, liver cancer was viewed as a neoplasm that almost exclusively arose among high-risk populations in low- and middle-income countries. Incidence rates in some high-risk populations, however, have been declining, while rates in low-risk populations have been increasing, reflecting changes in underlying etiology. In this review, we highlight the evolving epidemiology of liver cancer, focusing on recent research and advances. RECENT
findingsEfforts to reduce or eliminate the risk associated with major risk factors such as hepatitis B virus (HBV), hepatitis C virus (HCV) and aflatoxin B SUMMARY: While there has been progress in combating the effects of some risk factors, the increasing prevalence of others poses a major threat to attempts to tackle the rising incidence of liver cancer globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.